BRIEF-Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial

Feb 12 (Reuters) - AnaptysBio ANAB.O:

• ANAPTYS ANNOUNCES ROSNILIMAB ACHIEVED POSITIVE RESULTS IN RA PHASE 2B TRIAL AND HIGHEST EVER REPORTED CDAI LDA RESPONSE OVER 6 MONTHS

• ANAPTYSBIO INC - ROSINILIMAB SAFE AND WELL TOLERATED WITH SIMILAR ADVERSE EVENT RATES VERSUS PLACEBO

• ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON KEY SECONDARY ENDPOINTS AT WEEK 12

• ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 12

• ANAPTYSBIO INC - TOP-LINE WEEK 12 PHASE 2 ULCERATIVE COLITIS DATA FOR ROSNILIMAB EXPECTED IN Q4 2025

Source text: ID:nGNXc9Q9Gv

Further company coverage: ANAB.O